In all, 78 peripheral hematopoietic progenitor cell collections from 52 patients were evaluated using our previously published validated post-thaw assays at the time of collection and following transplantation by assessment of viable CD34 þ cells, and granulocytemacrophage colony-forming units (CFU-GM) cryopreserved in quality control vials. The median (range) post-thaw recovery of viable CD34 þ cells and CFU-GM was 66.4% (36.1-93.6%) and 63.0% (28.6-85.7%), respectively, which did not show significant correlation with the engraftment of either neutrophils (P ¼ 0.136 and 0.417, respectively) or platelets (P ¼ 0.88 and 0.126, respectively). However, the reinfused viable CD34 þ cells/ kg of patient weight pre-or post-cryopreservation showed significant correlation to engraftment of neutrophils (P ¼ 0.0001 and 0.001, respectively) and platelets (P ¼ 0.023 and 0.010, respectively), whereas CFU-GM pre-or post-cryopreservation was significantly correlated to neutrophils (P ¼ 0.011 and 0.007, respectively) but not to platelets (P ¼ 0.112 and 0.100, respectively). The results show that post-cryopreservation assessment of viable CD34 þ cells or CFU-GM is as reliable a predictor of rapid engraftment as that of pre-cryopreservation measures. Therefore, the post-cryopreservation number of viable CD34 þ cells or CFU-GM should be used to eliminate the risks of unforeseen cell loss that could occur during cryopreservation or long-term storage.
CD34
þ ; CFU-GM A minimum number of CD34 þ cells is required for rapid hematologic recovery following myeloablative therapy for hematologic malignancies. 1 Some studies have reported that 2.5-5.0 Â 10 6 CD34 þ cells/kg is associated with rapid engraftment, [1] [2] [3] but the minimum CD34 þ cells/kg for autologous peripheral blood progenitor cell transplantation has not been defined or standardized. An obstacle in defining such threshold is that the quantification of CD34 þ cells has been performed pre-cryopreservation. As the extent of loss of viable CD34 þ cells after thawing is not assessed, the actual number of viable CD34 þ cells infused into patients is not known. Some studies have compared CD34
þ cell number and colony growth before and after cryopreservation of peripheral hematopoietic progenitor cells (HPC), 4, 5 and concluded that post-thaw CD34 þ cell number may be useful in monitoring cell loss during cryopreservation. 4, 6, 7 However, the results reported showed that viable CD34 þ cells after cryopreservation did not decrease but instead increased by up to 77%. 5 In addition, the reported viability of CD34 þ cells varied from 0 to 304%. 4, 8 This wide variation of the post-cryopreservation viability resulted from the post-thaw assessment assays being based on the number of nucleated cells remaining after cryopreservation. 9, 10 However, the number of nucleated cells, particularly neutrophils, is decreased during cryopreservation and during post-thaw incubation due to cell loss and clumping of the damaged cells. 11, 12 In dual-platform CD34 þ enumeration assays, this decrease in the number of nucleated cells results in an apparent increase in the percentage of CD34 þ cells when nucleated cell count is used as the denominator to calculate the total post-cryopreservation CD34 þ cells. Even when using a validated single-platform CD34 þ enumeration technique to obtain absolute CD34 þ cells, assays did not account for cells lost during cryopreservation or post-thaw washing, 13 nor were comparisons made with proliferation of progenitor cells (granulocyte-macrophage colony-forming units (CFU-GM)). 7 In previous studies, 9, 10 we validated the use of post-cryopreservations assays for assessing postcryopreservation viability of CD34 þ cells and CFU-GM with high accuracy. 7 It is our hypothesis that post-thaw assessment of CD34 þ cell viability and CFU-GM may be a more accurate method to predict hematopoietic engraftment. In this study, we assessed 78 consecutive collections of autologous HPCs from 52 patients before and after cryopreservation using validated post-cryopreservation assays to investigate the association of viability of CD34 þ cells and CFU-GM with hematopoietic engraftment.
Materials and methods

Patients
This study was conducted using a protocol reviewed by the Health Research Ethics Board of the University of Alberta. A total of 52 patients autografted with cryopreserved HPC after myeloablative doses of chemotherapy without total body irradiation (TBI) were analyzed. Clinical characteristics of the 52 patients are reported in Table 1 . At the beginning of the conditioning regimen, all patients were in remission of either a multiple myeloma (n ¼ 28), Hodgkin's (n ¼ 10), lymphoma (n ¼ 9), a solid tumor (n ¼ 4) or amyloidosis (n ¼ 1). 
Mobilization and collection of HPC
High-dose regimens
Patients received high-dose chemotherapy without TBI followed by autologous HPC infusion. 
Cryopreservation
A stock cryopreservation solution consisting of 30% dimethyl sulfoxide (DMSO) (Edwards Lifesciences, Irvine, CA, USA) and 70% Plasma-Lyte A (Baxter, Toronto, Canada) was prepared fresh for each HPC product. An HPC component with p600 Â 10 6 cells/ml nucleated cells without any further manipulation was slowly mixed with the stock DMSO solution, which was half the volume of the HPC component (1:3 dilution) to achieve a final concentration of 10% DMSO. The HPC with 10% DMSO were divided into cryocyte-freezing containers (Nexell, Irvine, CA, USA) and three vials were prepared as quality control. The cells were cooled at 11C/min to À301C and then 51C/min to À701C using a controlled-rate freezer (CyoMed 1010, Forma Scientific, Marjetta, OH, USA). The frozen samples in the bags and vials were stored in a liquid nitrogen freezer (oÀ1501C) under the same conditions until reinfusion. Following reinfusion of the component, the cells in quality control vials were thawed (2507101C/min) in a 371C water bath until visible ice was melted. DMSO was removed from the thawed cells through stepwise dilution with phosphate-buffered saline (PBS) containing 2% fetal bovine serum and no calcium chloride or magnesium chloride (StemCell Technologies, Vancouver, Canada). Dilution was performed by adding 20% (1/5 dilution), 33% (1/3 dilution) and 25% (1/4 dilution) proportion by volume of PBS to the thawed cells with þ cells for growth of CFU-GM were adjusted accordingly.
Viability assays
The cells were assessed on the day of collection (precryopreservation; control) for absolute viable CD34
þ cell enumeration and CFU-GM colony growth. Post-cryopreservation samples were subjected to the same manipulation as the pre-cryopreservation samples regardless of the concentration of nucleated cells in the post-thaw samples, thereby avoiding errors introduced by changes to the cell population during cryopreservation.
Absolute CD34
þ count. Single-platform flow cytometric absolute CD34
þ cell counts were performed as described by Keeney et al.
14 Briefly, 100 ml of the nucleated cell suspension (corresponding to 10-15 Â 10 6 cells/ml in the control samples) from control or post-cryopreservation samples were treated with 20 ml of either CD34-PE (580 clone)/CD45-FITC (J33 clone) or CD45-FITC/Isoclonic PE followed by 20 ml of 7-amino-actinomycin D (7-AAD, 1 mg/ml, Molecular Probes, Eugene, OR, USA), and then incubated at room temperature for 20 min in the dark. In all, 2 ml of 10% ammonium chloride were then added to the tubes and the tubes were incubated for an additional 10 min at room temperature in the dark. After incubation, 100 ml of Coulter Stem-Count beads was added to each tube, incubated in ice/water bath for 5 min and flow cytometric analysis was performed immediately on a Coulter EPICS XL/MCL cytometer.
Evaluation of CFU-GM. A clonogenic assay was performed using a progenitor assay medium (MethoCultt GF H4444, StemCell Technologies, Vancouver, Canada). Precryopreservation samples contained 500 CD34 þ cells. A volume of the post-cryopreservation sample that corresponded to a pre-cryopreservation count of 1 Â 10 3 CD34
þ cells was used to avoid performing a post-cryopreservation count. Samples were plated in duplicate in 35-mm culture dishes and the actual viable CD34 þ cells/plate were calculated based on viability assessed by flow cytometry. The dishes were incubated at 371C in a humidified 5% CO 2 incubator for 14 days and CFU-GM colonies were counted using an inverted microscope.
Calculation of viability
Viability was defined as the absolute number of viable cells (or colonies) that are retained following cryopreservation and is calculated as follows: 
CD34
þ cells pre-and post-cryopreservation were compared by using one-way analysis of variance. Correlations between number of post-thaw viable CD34 þ cells and CFU-GM, cell doses (per body weight) of viable CD34 þ cells and CFU-GM pre-and post-cryopreservation, and relationship of the post-thaw recoveries (%) or cell dose (per body weight) of viable CD34 þ and CFU-GM to time to neutrophil and platelet recovery was analyzed by using the Pearson correlation test. The time to neutrophil engraftment is defined as the day on which the sustained ANC first reached X0.5 Â 10 9 cells/l for 3 consecutive days, and platelet engraftment is defined as the time to reach platelet X20 Â 10 9 cells/l without prior platelet transfusion for 2 consecutive days. Significance was set at Po0.05.
Results
Correlation of CD34
þ cells and CFU-GM before and after cryopreservation
Mean frequencies of CFU-GM/0.5 Â 10 3 CD34 þ cells before and after cryopreservation were 72.6721.4 and 62.3722.6, respectively, representing a significant (P ¼ 0.007) reduction in CFU-GM during cryopreservation. After thawing, the number of CFU-GM and viable CD34 ), respectively. The median (range) time to neutrophil and platelet engraftment was 12 days (7-14) and 12 days (7-24), respectively. As shown in Figure 4a and b, the neutrophil engraftment was significantly correlated with number of CD34 þ cells/kg (P ¼ 0.0001) and CFU-GM/kg (P ¼ 0.011) before cryopreservation, but rapid platelet engraftment was only correlated to the number of CD34 þ cells/kg (P ¼ 0.023) but not CFU-GM/kg (P ¼ 0.112). Following cryopreservation, Figure 5a and b shows the same correlations of neutrophil and platelet engraftment as those of pre-cryopreservation in both the number of viable CD34 þ cells/kg (P ¼ 0.001 and 0.010, respectively) and CFU-GM/kg (P ¼ 0.007 for neutrophil engraftment). We did not observe a significant correlation of number of postcryopreservation CFU-GM/kg with platelet engraftment (P ¼ 0.10).
Discussion
A minimum number of CD34 þ cells has not been clearly established for rapid and sustained engraftment after autologous stem cell transplantation, although 2-5 Â 10 6
CD34
þ cells/kg has been defined by some investigators for rapid hematopoietic recovery. [15] [16] [17] One of the reasons that a minimum of CD34 þ cells has not been established could be that the number of CD34 þ cells is quantified before cryopreservation. At least two conditions have to be met to determine the optimal number of CD34 þ cells based on quantification of CD34 þ cells before cryopreservation in autologous transplant. One is that the number of viable CD34 þ cells has to be the same before and after cryopreservation, and the other is that the number of CD34 þ cells lost between collection and transplant is known and can be compensated for by increasing the collection of CD34 þ cells. However, the inevitable loss of CD34 þ cells between collection and transplant, especially during cryopreservation, is difficult to predict without assessment of the sample after cryopreservation. 4, 5, 7, 8, 18 This leads to the current debate as to whether the quantification of HPC should be performed before or after cryopreservation.
Investigators 4, 5, 7, 8, 18 who have studied post-thaw CD34 þ cells and hematopoietic recovery have found that there was a significant link between the number of CD34 þ cells after cryopreservation and neutrophil and platelet engraftment. It has been proposed 6 that the number of CD34 þ cells should be determined after cryopreservation, and that at least the loss of HPC should be monitored. However, these studies showed considerable variability (0-304%) after cryopreservation 4 and an increased mean of 1.22% viable CD34 þ cells before cryopreservation to a mean of 2.16% after cryopreservation. 5 Other studies 4, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] have shown more convincing results, but the washing of the postcryopreservation component for the enumeration of CD34 þ cells does not represent the actual number of CD34 þ cells in the DMSO-containing HPC products that are infused in the patients. The above procedures used for CD34 þ cell enumeration and CFU-GM assay (if performed) had not been validated and standardized, and the increased viability after cryopreservation (4100%) made the proposal even more dubious. 4, 5, 20 Our previous studies have validated the assays for the post-cryopreservation assessment of CD34 þ cells and CFU-GM in HPC by eliminating variability inducing factors and defining assay conditions. 9, 10, 13 In this study, we used validated assays to assess HPC components (52 patients) stored in quality control vials, and correlated the percent of recovery and infused dose of viable CD34
þ cells and CFU-GM/kg of patient weight with neutrophil and platelet engraftment. Cells stored in vials have been shown to be representative of cells stored in freezing bags. 8, 21 Using these cells also reduces risk to patients when severe problems are found at the time of transplant or after transplant by assessment of HPC. The assessment of cells in quality control vials is practical because these cells, which are stored at the same conditions as the HPC for transplant, can be assessed at any time between cryopreservation and transplant, and therefore useful for supporting decisions on transplantation.
We observed a significant correlation between the number of viable CD34 þ cells and CFU-GM (r ¼ 0.48, P ¼ 0.0001), and the mean frequencies of CFU-GM/ 0.5 Â 10 3 viable CD34 þ after cryopreservation remained at 85.8%. Owing to the prolonged nature of the CFU-GM assay, it is not practical to use this test to determine the optimal number of HPC needed for an autologous transplant. The lack of reproducibility, especially after cryopreservation if a washing procedure to remove DMSO is involved in the assay, further affects the clinical use of the CFU-GM assay. From our previous work, we found that there was a significant correlation between CD34 þ cells and CFU-GM, and that the number of CD34 þ cells postcryopreservation was not affected by incubation for up to 2 h at 0, 22 or 371C. 10 The CFU-GM assay in this study was based on 0.5 Â 10 3 CD34 þ cells/plate before cryopreservation and a corresponding 1 Â 10 3 CD34 þ cells/plate by serial dilution without any other manipulation after cryopreservation. This allowed the recovery of viable CD34 þ cells to be related directly to the control samples, and to the actual number of viable cells plated. The growth of CFU-GM/0.5 Â 10 3 viable CD34 þ cells ranged from 27 to 121 in the 78 leukapheresis units. The number of CFU-GM in collections from the same patients did not show significant difference before or after cryopreservation (P ¼ 0.21 and 0.22, respectively). This indicates that frequencies of CFU-GM vary from patient to patient but not between leukapheresis from the same patient. The procedure, therefore, makes this assay a reliable means to compare the recovery of CFU-GM before and after cryopreservation, for a given leukapheresis unit or patient.
The median recovery of viable CD34 þ cells after cryopreservation was 66.4% with a range of 36.1-93.6%. There were four patients whose recovery of viable CD34 þ cells was below 50% (42.875.67%), but both neutrophil and platelet engraftment were 12 days, and hence was not significantly different from those patients with higher cell recovery (450%) (P ¼ 0.43 and 0.23, respectively). This implies that low recovery of viable CD34 þ cells after cryopreservation is not a factor in delayed hematopoietic recovery at the cell doses used in our transplants. The median recovery of CFU-GM was 63.0 (range, 28.6-85.7%). In patients with recovery of CFU-GM below 50% (35.378.45), the time to neutrophil and platelet engraftment were both 12 days and did not show significant difference with CFU-GM recovery X50% (P ¼ 0.33 and 0.67, respectively). The reason that the time to engraftment for recovery below 50% in CD34 þ cells or CFU-GM was not significantly different in this study was because the cell doses were high at 3.9272.46 Â 10 6 CD34 þ cells/kg compared to the reported 21 2.8271.36 Â 10 6 CD34 þ cells/ kg that showed slow hematologic engraftment. Rather than making decisions on repeat collections using CD34 þ counts on fresh samples, a stronger strategy would be to base these decisions on viable CD34
þ counts in cryopreserved samples. For the most reliable and accurate determination of the viability of CD34 þ cells, samples should be evaluated immediately before performing stem cell transplant, but this would be too late to correct any risk to patients from loss of HPC during cryopreservation. It has been shown that cord blood stem cells cryopreserved and stored in liquid nitrogen freezers for 5, 10 and 15 years had no significant difference in cell viability or proliferation, [22] [23] [24] indicating that loss of cells occurred during freezing and thawing, and not during storage. Since rapid engraftment has been shown to be significantly correlated to the dose of viable CD34 þ cells/ kg infused, the results presented in this study lead to the conclusion that assessment of cryopreserved HPC should be performed immediately after cryopreservation processing to support decisions on subsequent collections, to ensure that a minimum number of viable CD34 þ cells are banked and available for transplantation.
There were no graft failures or slow engraftments in the 52 patients involved in this study because all patients were reinfused with X2 Â 10 6 /viable CD34 þ cells/kg and 41 Â 10 5 CFU-GM/kg; therefore, no lower threshold for successful engraftment for either viable CD34 þ cells or CFU-GM can be defined from this study.
In summary, this study supports the proposal that the quantification of viable CD34 þ cells or CFU-GM should be assessed after cryopreservation even though precryopreservation CD34 þ cells/kg BW significantly correlated with engraftment. Post-thaw qualification of viable CF34 þ cells or CFU-GM can eliminate the risks of unforeseen cell loss that could occur during cryopreservation or long-term storage in liquid nitrogen freezers. Owing to the potential loss of viable CD34 þ cells during low temperature storage, we recommend that CD34 þ assessment be performed prior to transplantation to decrease the possibility of engraftment failure by adjusting posttransplant treatment protocols. In addition, we strongly recommend that the assessment of viable CD34 þ cells be performed immediately after cryopreservation processing to ensure sufficient HPCs are collected for successful hematopoietic engraftment.
